Development of organoid-based drug metabolism model

• Published in: Toxicology and applied pharmacology 2019-12, Vol.385, p.114790, Article 114790
• Main Authors: Park, Enoch, Kim, Han Kyung, Jee, JooHyun, Hahn, Soojung, Jeong, Sukin, Yoo, Jongman
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic Agents - metabolism; beta-Naphthoflavone - pharmacology; Cell Survival - drug effects; CYP; Cytochrome P-450 Enzyme System - physiology; Dexamethasone - pharmacology; Drug metabolism; Humans; Intestinal Mucosa - metabolism; Liver - metabolism; Male; Mice; Mice, Inbred C57BL; Organoid; Organoids - metabolism; Pancreatic Neoplasms - drug therapy; Pancreatic Neoplasms - pathology; Toxicological model
• ISSN: 0041-008X; 1096-0333
• DOI: 10.1016/j.taap.2019.114790

Cytochrome P450 (CYP) gene superfamily catalyzes oxidative metabolism of a wide variety of drugs, carcinogens, and endogenous biomolecules in the liver and intestinal organs. In vitro assay platforms such as primary hepatocyte and immortalized liver-derived cell lines have been developed to evaluate drug effects. However, several limitations have been suggested regarding discrepancies between in vitro and in vivo assays. In this study, we aimed to investigate drug metabolism and toxicity based on mouse small intestinal and liver organoids derived from resident stem cells. At first, expressions and activities of CYP subfamilies (CYPs) in intestinal and liver organoids were investigated. Organoids treated with three CYPs-inducers dexamethasone (Dex), β-naphthoflavone (BNF), and 1,4-bis-2-(3, 5-dichloropyridyloxy)-benzene (TCPOBOP) were evaluated for CYPs activities. The CYPs-induced intestinal and liver organoids were confirmed to digest more docetaxel, as colon cancer cell-line survived more in CYPs-induced organoid's medium than in non-induced organoid's medium. Then, the activity of docetaxel in a co-culture platform of mouse liver organoids and human pancreatic tumoroids was measured. We obtained significant statistical values on CYPs-induced metabolic activities: cell survival rates of pancreatic tumoroids co-cultured with docetaxel-treated undifferentiated, differentiated, and CYPs-induced differentiated organoids were 66.05 ± 2.14%, 89.20 ± 2.67%, and 101.90 ± 0.94%, respectively. To sum up, gene expression modification and drug metabolism evaluation were able to be done with organoids as done with tissues. In vivo-like in vitro investigation on drug toxicity may potentially be done with organoids as a stepping bridge to the clinical trial. [Display omitted] •Constructed organoids express all important cellular markers of its origin.•Metabolic proteins can be induced in organoids to digest more drugs.•Pharmacodynamics can be assessed using organoid-based toxicological model.